MRK - Jazz Announces Topline Data And Other News: The Good Bad And Ugly Of Biopharma
- Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial.
- MacroGenics reports positive data for flotetuzumab immunotherapy.
- Merck provides updated positive data for Keytruda in lung cancer.
For further details see:
Jazz Announces Topline Data, And Other News: The Good, Bad And Ugly Of Biopharma